Oxitec modifies Aedes aegypti mosquitoes with synthetic DNA to produce offspring that won't survive outside a lab.
MIAMI (AP) — A field trial releasing genetically modified mosquitoes in the Florida Keys would not harm humans or the environment, according to documents released Friday by the U.S. Food and Drug Administration.
The agency’s Center for Veterinary Medicine released a preliminary finding of no significant impact for the trial of a method that aims to reduce populations of the mosquito that spreads dengue, chikungunya and the Zika virus among humans. The trial is proposed by the British biotech firm Oxitec. The Florida Keys Mosquito Control District wants to test Oxitec’s mosquitoes in a small neighborhood north of Key West.
The FDA still needs to review public comments before deciding whether to approve the trial. But the tentative approval could make it easier explore similar trials in the Southeast or Puerto Rico, said Oxitec CEO Haydn Parry.
“Time is not on our side here, if you look at how Zika has been spreading in Brazil and other countries,” Parry said in a conference call with reporters. “The sooner we can start the trial, the sooner we show what we can do.”
Most Read Stories
- Seattle judge won’t immediately release ‘Dreamer’ from detention center
- Officials say damage to sewage plant in Discovery Park is catastrophic
- T-Mobile one-ups Verizon’s new unlimited data plan; 4Q results top forecasts
- Sticker shock as much higher car-tab bills land in mailboxes
- Mexico City is a parched and sinking capital
Oxitec modifies Aedes aegypti mosquitoes with synthetic DNA to produce offspring that won’t survive outside a lab. Oxitec has conducted similar tests in Panama, Brazil and the Cayman Islands.
With or without the test, the district is looking for additional options to kill Aedes aegypti, which it considers a significant and expensive threat. In a statement, executive director Michael Doyle said the district needs to be proactive, and the trial will need to determine how efficient Oxitec’s mosquitoes are at suppressing the local Aedes population.
“A small trial like this is designed to see if highly reducing the population is possible with this technology here in the Keys. If so, we will then look at larger trial areas,” Doyle said.
A residents’ group called the Florida Keys Environmental Coalition wants the district to instead try infecting mosquitoes with a bacteria that curbs their ability to transmit disease, arguing that Oxitec’s proposal is mostly marketing hype and won’t be subject to adequate federal oversight.
In an email Monday to The Associated Press, the coalition’s executive director, Barry Wray, questioned the ongoing costs Oxitec’s method might incur.
“Oxitec has exploited the fear surrounding Zika very effectively,” Wray wrote. “When you start looking at the quantity of mosquitoes they need to continuously provide, in order to keep problems under control, the numbers are astounding. So is the money required!”
Doyle said the district is investigating several different technologies for eradicating Aedes mosquitoes, but those other methods take years to develop and Oxitec is furthest along.
Oxitec developed the mosquito in 2002 and has been testing it outdoors since 2009, Parry said. The Keys district approached Oxitec about trying its technology in 2010.
The company will cover the costs of the Keys trial, if it is approved, and a lab in Marathon where its mosquitoes will be raised already has passed U.S. government inspections. The company’s application allows for a trial lasting up to 22 months, but trials elsewhere have reduced mosquito populations in about six months, Parry said.
Oxitec aims to eventually sell its mosquitoes and services in the way that other companies sell insecticides.
The Keys district spends over $1 million a year to suppress up to half its Aedes aegypti population. Oxitec’s method would not increase the district’s costs but it would boost their suppression rates up to 90 percent, Parry said.
Anti-GMO activists have criticized Oxitec’s trials, saying more proof is needed that stray female modified mosquitoes that leave the labs aren’t spreading genetic material through bites or that there are no other environmental risks, such as opening areas to infestation by another disease-carrying mosquito species.
Modified females are manually separated in Oxitec labs from the modified males, which do not bite and are released to mate with wild female mosquitoes.
In its preliminary finding, the FDA said it was “highly unlikely” that humans or animals bitten by female modified mosquitoes would be exposed to synthetic genetic material, and any bites wouldn’t be any different from bites made by a wild mosquito.
It’s also unlikely that suppressing the local Aedes population during the trial would open the area to an infestation of another disease-carrying species during that period, the FDA said.
The FDA also found no significant risks that the modified mosquitoes would disperse well beyond the trial area, develop resistance to insecticides or persist in the environment.
“Based on the data and information submitted in the draft (environmental assessment), other submissions from the sponsor, and scientific literature, FDA found that the probability of adverse impacts on human or other animal health is negligible or low,” the finding said.
A draft environmental assessment on Oxitec’s proposal will be available for public comment for 30 days. The FDA will review those comments and may require further documentation from Oxitec before deciding whether to approve that trial. There is no deadline for that decision, so no modified mosquitoes will be released anytime soon.
The Centers for Disease Control and Prevention and the Environmental Protection Agency also have reviewed the proposal along with the FDA.